Gilteritinib is included through EHA 2026 LB5005, the HOVON156/AMLSG28-18/PASHA Phase 3 head-to-head study versus midostaurin in newly diagnosed FLT3-mutated AML. The key interpretation is not clear superiority: official abstract text states OS was not significantly different and the primary endpoint was not met.
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.
Executive Summary
Gilteritinib (Xospata) is a second-generation Type I FLT3 / AXL dual tyrosine kinase inhibitor for relapsed or refractory FLT3-mutated acute myeloid leukemia. Astellas Pharma originated the molecule. The FDA granted approval on 2018-09-21 based on the ADMIRAL Phase 3 trial, which demonstrated overall survival benefit over salvage chemotherapy. Gilteritinib subsequently became the standard relapsed-or-refractory FLT3-mutated AML monotherapy in the US, EU, and Japan.
Notably, the Patsnap Eureka pharma-intelligence stack returns 311 FLT3-targeting drug records, 1,093 FLT3-related patents filed since January 2023, and 27 active Phase 2 or Phase 3 trials with gilteritinib as the main investigational drug. Within that pool, four FDA-approved FLT3 inhibitors compete: midostaurin (Novartis, 2017, frontline with chemo), gilteritinib (Astellas, 2018, R/R), quizartinib (Daiichi Sankyo, 2019/2023, frontline), and a long preclinical or relapsed-or-refractory tail (crenolanib, lestaurtinib, sorafenib, sunitinib, ENMD-2076).
As a result, EHA 2026 LB5005 (HOVON156 / AMLSG28-18 / PASHA) reframes the gilteritinib story. The Phase 3 head-to-head versus midostaurin in newly diagnosed FLT3-mutated AML did not meet its OS primary endpoint. The strategic question is no longer whether gilteritinib replaces midostaurin in frontline. Instead, it shifts to subgroup interpretation, EFS or RFS gain, transplant-pathway differences, and how Daiichi Sankyo’s quizartinib and emerging FLT3 PROTAC degraders take share next.
Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated — from extracting molecules to mapping competitive pipelines — into a structured output like the report below.
Arena Overview
Gilteritinib MoA snapshot — Gilteritinib is an oral small-molecule Type I FLT3 inhibitor with potent activity against both internal tandem duplication (FLT3-ITD) and tyrosine kinase domain (FLT3-TKD, including D835) mutations. As a result, it covers the two most common activating FLT3 alterations seen in acute myeloid leukemia. Crucially, gilteritinib also inhibits AXL, which contributes to compensatory survival signaling and resistance to first-generation FLT3 inhibitors.
FLT3-targeting field (311 records) — Among FLT3-targeting drug records, four approved FLT3 inhibitors anchor the AML market: midostaurin (Novartis Rydapt, 2017, frontline with 7+3 chemotherapy), gilteritinib (Astellas Xospata, 2018, R/R monotherapy), quizartinib (Daiichi Sankyo Vanflyta, FDA 2023 frontline / Japan 2019 R/R), and lestaurtinib (legacy, never broadly approved). Crenolanib (Arog Pharmaceuticals) is the closest Phase 3 challenger. Investigational FLT3 PROTAC degraders (BRM-1420, FHND-91, HMPL-760-class) and combinations with venetoclax + azacitidine drive the next wave.
FLT3 patent activity (since 2023) — In addition, assignees have filed 1,093 FLT3-related patent families since January 2023. The filings span next-generation Type II FLT3 inhibitors, FLT3 PROTAC degraders, FLT3-CD33 dual targeting, and combination protocols pairing FLT3 inhibition with venetoclax, hypomethylating agents, IDH inhibitors, and menin inhibitors.
Player Summary Table
| Player | Region | Tier | Primary Route | Key Evidence |
|---|---|---|---|---|
| Astellas Pharma (Xospata) | JP | T1 (Leader, R/R) | Type I FLT3 / AXL inhibitor | Gilteritinib (2018-09-21); ADMIRAL OS benefit; HOVON156/PASHA EHA 2026 LB5005 frontline did not meet OS primary endpoint |
| Novartis (Rydapt) | CH | T1 (Leader, frontline) | Multikinase FLT3 inhibitor | Midostaurin (2017-04-28); RATIFY frontline FLT3-mutated AML standard with 7+3 induction |
| Daiichi Sankyo (Vanflyta) | JP | T1 (Frontline challenger) | Type II FLT3 inhibitor | Quizartinib (Japan 2019, FDA 2023); QuANTUM-First frontline OS gain; QuANTUM-R R/R |
| Arog Pharmaceuticals | US | T2 (Phase 3 challenger) | Type I FLT3 inhibitor | Crenolanib — Phase 3; closest non-approved direct competitor in FLT3-mutated AML |
| BMS / Celgene (Venetoclax+Aza partner) | US | T1 (Adjacent backbone) | Hypomethylating agent | Azacitidine in VIALE-A; combination partner for FLT3i in older adults with AML |
| AbbVie (Venclexta) | US | T1 (Adjacent backbone) | BCL2 inhibitor | Venetoclax + gilteritinib trials (LACEWING); fills the BCL2 + FLT3i combination role |
Multikinase Challengers and Watchlist Players
| Player | Region | Tier | Primary Route | Key Evidence |
|---|---|---|---|---|
| Hanmi / Aptose (Tuspetinib) | KR/US | T2 (Multi-kinase challenger) | FLT3 / SYK / JAK inhibitor | Tuspetinib + venetoclax in TUSCANY (EHA 2026); polypharmacology positioning |
| Bayer / Onyx (Sorafenib) | DE/US | T2 (Off-label) | Multikinase TKI | Sorafenib (2005-12-01); SORAML and SORMAIN trials in FLT3-ITD post-transplant maintenance |
| Pfizer / Shionogi (Quizartinib JP) | JP | T2 (Regional) | FLT3 inhibitor | Quizartinib monotherapy launch path in Asia preceded US approval |
| BeiGene / BeOne | CN | T3 (Regional follower) | FLT3 inhibitor | HMPL-760, NMS-03592088 — China/Asia regional FLT3 candidates |
| Curis (Emavusertib) | US | T3 (IRAK4 + FLT3) | IRAK4 / FLT3 dual inhibitor | Emavusertib — Phase 1/2 in AML; combination with venetoclax |
| Brenus Pharma (BRM-1420) | FR | T3 (Watchlist) | FLT3 small molecule | BRM-1420 — preclinical; AML and other FLT3-driven malignancies |
| FuKai Yi Bio (Flunotinib) | CN | T3 (Regional follower) | FLT3 inhibitor | Flunotinib maleate — China-led FLT3 candidate |
| Aceragen (Lestaurtinib legacy) | US | Watchlist | FLT3 multikinase | Lestaurtinib — historic FLT3 chemistry; never broadly approved |
| UT Southwestern / Academic PROTACs | US | Watchlist | FLT3 PROTAC degraders | 2023+ patent filings on FLT3 PROTAC scaffolds; preclinical for resistance management |
Generate Competitive Landscape Reports Like This — in Minutes
Powered by Eureka LS AI
- ✔ Analyze patents, literature, and pipelines together
- ✔ Extract molecule & SAR data automatically
- ✔ Compare competitors and identify key assets
- ✔ Get structured reports instantly
Route Differentiation Analysis
In particular, four therapeutic routes define how gilteritinib competes within FLT3-mutated AML. Each strength level draws from MCP pipeline records and the published trial evidence.
Route × Player Matrix
| Player | Type I FLT3 Inhibitor | Type II FLT3 Inhibitor | FLT3 + BCL2 Combination | FLT3 + HMA Combination | FLT3 PROTAC Degrader |
|---|---|---|---|---|---|
| Astellas (Xospata) | Strong — Gilteritinib (R/R monotherapy) | Absent | Strong — LACEWING (Gilt + Aza ± Ven) | Strong — Gilt + azacitidine | Absent |
| Novartis (Rydapt) | Strong — Midostaurin (frontline + 7+3) | Absent | Moderate — Mido + Ven cohorts | Moderate — Mido + Aza in older adults | Absent |
| Daiichi Sankyo (Vanflyta) | Absent | Strong — Quizartinib (frontline + R/R) | Moderate — QuANTUM-First + Ven studies | Moderate — Quiz + Aza + Ven (QUIWI) | Absent |
| Arog Pharmaceuticals | Strong — Crenolanib Phase 3 | Absent | Emerging — crenolanib + venetoclax cohorts | Emerging — crenolanib + 7+3 | Absent |
| Hanmi / Aptose (Tuspetinib) | Moderate — TUSPETIB-302 multikinase | Absent | Strong — TUSCANY tuspetinib + venetoclax | Emerging | Absent |
| AbbVie + Astellas / Novartis (Venetoclax partner) | Absent | Absent | Strong — Venetoclax pairs with each FLT3i | Absent | Absent |
| BeiGene / BeOne / HMPL-760 | Emerging — HMPL-760 | Absent | Absent | Absent | Absent |
| Curis (Emavusertib) | Moderate — IRAK4/FLT3 dual inhibitor | Absent | Emerging — Emavusertib + venetoclax | Absent | Absent |
| Bayer / Onyx (Sorafenib) | Moderate — off-label post-transplant maintenance | Absent | Absent | Absent | Absent |
| Academic / UT Southwestern | Absent | Absent | Absent | Absent | Strong — FLT3 PROTAC scaffolds in 2023+ patents |
Route Concentration Observations
- Type I FLT3 inhibitors — Additionally, gilteritinib and crenolanib both bind the active conformation of FLT3 and remain effective against the D835 TKD mutation. Quizartinib (Type II) loses activity in the same setting.
- Type II FLT3 inhibitors — Meanwhile, quizartinib binds the inactive conformation. As a result, it shows higher specificity for FLT3-ITD but no activity against TKD point mutations. Daiichi Sankyo positions Vanflyta in frontline, which avoids the resistance setting where Type I shines.
- FLT3 + BCL2 combinations — In contrast, venetoclax pairs with every FLT3 inhibitor in active development. LACEWING (gilt + aza + ven), QUIWI (quiz + aza + ven), and TUSCANY (tuspetinib + ven) all test the same combination logic. The clinical question is which FLT3i partners best with the BCL2 backbone.
- FLT3 + HMA combinations — Similarly, azacitidine pairs with FLT3 inhibitors for older adults with AML who cannot tolerate intensive induction. The triplet (FLT3i + Ven + Aza) builds on the VIALE-A AML standard.
- FLT3 PROTAC degraders — Furthermore, 2023+ patent filings show academic and biotech interest in FLT3 PROTACs that degrade resistance variants. None has reached clinical trials yet.
Top Player Deep Dives
1. Astellas Pharma — Gilteritinib (Tier 1 — R/R monotherapy leader)
Primary route: Type I FLT3 / AXL dual tyrosine kinase inhibitor anchored to relapsed or refractory FLT3-mutated AML.
Key product: Gilteritinib (Xospata, 2018-09-21) — FDA approval based on ADMIRAL Phase 3, which demonstrated overall survival benefit (median OS 9.3 vs 5.6 months, HR 0.64) versus salvage chemotherapy in relapsed or refractory FLT3-mutated AML.
Pivotal trials: ADMIRAL (Phase 3 R/R monotherapy); LACEWING (gilteritinib + azacitidine vs azacitidine alone in newly diagnosed FLT3-mutated AML who are unfit for intensive chemotherapy); HOVON156 / AMLSG28-18 / PASHA (EHA 2026 LB5005, Phase 3 head-to-head vs midostaurin in newly diagnosed FLT3-mutated AML, OS primary endpoint not met).
Differentiation: Notably, gilteritinib covers both FLT3-ITD and FLT3-TKD (D835) mutations and adds AXL inhibition. As a result, it preserves activity in patients whose disease has progressed on first-generation FLT3 inhibitors.
Trajectory: Moreover, Astellas now positions gilteritinib in post-transplant maintenance (MORPHO Phase 3) and in combination with venetoclax + azacitidine for older adults with AML. The HOVON156/PASHA frontline miss limits direct frontline replacement of midostaurin but does not affect the R/R monotherapy core franchise.
Key risk: However, Daiichi Sankyo’s quizartinib already holds frontline approval. Crenolanib’s pending Phase 3 readouts could fragment the Type I segment. FLT3 PROTAC degraders threaten longer-term displacement.
FLT3 Inhibitor Generational Comparison
| Agent | Generation | Type | FDA Approval | Lead Setting |
|---|---|---|---|---|
| Sorafenib (off-label) | 1st-gen multikinase | Type II | 2005-12-01 (RCC, not AML label) | FLT3-ITD post-transplant maintenance (off-label) |
| Midostaurin (Rydapt) | 1st-gen FLT3i | Type I multikinase | 2017-04-28 | Frontline FLT3-mutated AML with 7+3 |
| Gilteritinib (Xospata) | 2nd-gen FLT3i | Type I + AXL | 2018-09-21 | R/R FLT3-mutated AML monotherapy |
| Quizartinib (Vanflyta) | 2nd-gen FLT3i | Type II selective | JP 2019; FDA 2023-07-20 | Frontline FLT3-ITD AML with chemo + maintenance |
| Crenolanib | 2nd-gen FLT3i | Type I | Phase 3 | R/R FLT3-mutated AML; frontline + 7+3 testing |
2. Novartis — Midostaurin (Tier 1 — Frontline incumbent)
Primary route: First-in-class multikinase inhibitor with FLT3 activity.
Key product: Midostaurin (Rydapt, 2017-04-28) — FDA approval based on RATIFY for newly diagnosed FLT3-mutated AML in combination with 7+3 induction and consolidation.
Differentiation: Specifically, midostaurin holds the frontline FLT3-mutated AML standard for fit patients receiving intensive induction. RATIFY established the 25% relative OS benefit that defines current guideline care.
Trajectory: In addition, the EHA 2026 HOVON156 / AMLSG28-18 / PASHA readout — gilteritinib failed to beat midostaurin on OS — protects Novartis’s frontline franchise. Quizartinib’s QuANTUM-First win remains the bigger long-term threat.
Key risk: However, midostaurin lacks selectivity, which causes off-target tolerability burden. Quizartinib offers the cleaner Type II profile in frontline.
3. Daiichi Sankyo — Quizartinib (Tier 1 — Frontline challenger)
Primary route: Type II selective FLT3 inhibitor.
Key product: Quizartinib (Vanflyta) — Japan approval 2019 for R/R FLT3-ITD AML; FDA approval 2023-07-20 for newly diagnosed FLT3-ITD AML based on QuANTUM-First Phase 3 OS gain (31.9 vs 15.1 months).
Differentiation: Notably, Daiichi Sankyo holds the only Type II FLT3 inhibitor with frontline OS evidence. The selectivity reduces midostaurin’s off-target tolerability burden.
Trajectory: Furthermore, Daiichi Sankyo runs QuANTUM-Aza (with azacitidine + venetoclax) and post-transplant maintenance trials. Vanflyta has the strongest frontline-displacement evidence in FLT3-ITD AML.
Key risk: However, quizartinib lacks activity against FLT3-TKD mutations. R/R disease that progresses through D835 mutations escapes quizartinib but remains gilteritinib-sensitive.
4. Arog Pharmaceuticals — Crenolanib (Tier 2 — Phase 3 challenger)
Primary route: Type I FLT3 inhibitor.
Key product: Crenolanib — Phase 3 in R/R and frontline FLT3-mutated AML. Arog runs combination trials with 7+3 induction and with venetoclax + azacitidine.
Differentiation: In particular, crenolanib retains activity against both FLT3-ITD and FLT3-TKD mutations and shows preserved potency in tertiary resistance settings. The Type I selectivity profile is the closest mechanistic match to gilteritinib.
Trajectory: Specifically, a positive Phase 3 readout would create direct competition with gilteritinib for R/R monotherapy and with midostaurin for frontline + 7+3 combinations.
Key risk: However, the development gap behind gilteritinib is significant. Crenolanib will arrive into a market already shaped by ADMIRAL, QuANTUM-First, and HOVON156 readouts.
5. Aptose / Hanmi — Tuspetinib (Tier 2 — Multi-kinase challenger)
Primary route: Triple kinase inhibitor (FLT3 / SYK / JAK1-2).
Key trial: TUSCANY (EHA 2026 entry) — combines tuspetinib with venetoclax in AML. The polypharmacology positioning targets pathways beyond FLT3, including SYK-driven survival and JAK-mediated cytokine signaling.
Differentiation: Specifically, tuspetinib hits FLT3 plus SYK plus JAK simultaneously. The combination addresses non-FLT3 myeloid kinase dependencies that emerge as resistance.
Trajectory: Furthermore, Aptose pairs tuspetinib with venetoclax for ven-refractory or post-FLT3i AML. The strategy hedges across multiple resistance mechanisms.
Key risk: However, multikinase inhibitors carry tolerability burden. The Phase 3 path is still distant.
6. Curis — Emavusertib (Tier 3 — IRAK4 + FLT3 dual)
Primary route: IRAK4 / FLT3 dual inhibitor.
Key trial: Emavusertib (CA-4948) — Phase 1/2 in R/R AML, MDS, and B-cell malignancies. Combinations with venetoclax + azacitidine in older adults with AML.
Differentiation: Specifically, emavusertib targets IRAK4 (innate immune signaling) plus FLT3. The dual mechanism may address ven-resistance through alternative pathway inhibition.
Trajectory: Moreover, Curis runs FLT3-mutated and FLT3-wild-type cohorts to test whether IRAK4 alone drives benefit beyond FLT3 inhibition.
Key risk: However, emavusertib has had safety setbacks in earlier-stage trials. The path to Phase 3 will require careful tolerability management.
BD Deals & Strategic Moves
Key business development activity shaping the gilteritinib competitive landscape:
| Date | Deal | Parties | Type | Significance |
|---|---|---|---|---|
| 2017-04 | Midostaurin (Rydapt) FDA approval | Novartis | Regulatory | First FLT3 inhibitor approved for newly diagnosed FLT3-mutated AML with 7+3 |
| 2018-09 | Gilteritinib (Xospata) FDA approval | Astellas Pharma | Regulatory | First targeted monotherapy for R/R FLT3-mutated AML based on ADMIRAL Phase 3 OS gain |
| 2019-06 | Quizartinib Japan approval (R/R FLT3-ITD) | Daiichi Sankyo | Regulatory | Regional Type II FLT3 inhibitor approval ahead of US |
| 2023-07 | Quizartinib (Vanflyta) FDA approval (frontline) | Daiichi Sankyo | Regulatory | QuANTUM-First Phase 3 OS gain (31.9 vs 15.1 months); frontline FLT3-ITD AML standard challenge |
| 2024 | MORPHO Phase 3 readout (gilteritinib post-transplant maintenance) | Astellas | Pivotal trial | Tests gilteritinib in maintenance setting after allogeneic stem cell transplant |
| 2024-2026 | HOVON156 / AMLSG28-18 / PASHA enrollment + readout | HOVON / AMLSG / Astellas | EHA 2026 LB5005 pivotal trial | Phase 3 head-to-head gilteritinib vs midostaurin in newly diagnosed FLT3-mutated AML; OS primary endpoint NOT met |
| 2024-2026 | LACEWING Phase 3 (gilteritinib + azacitidine) | Astellas + BMS | Pivotal trial | Tests gilteritinib + azacitidine vs azacitidine alone in older adults with AML |
| 2024-2026 | QuANTUM-Aza (quizartinib + azacitidine + venetoclax) | Daiichi Sankyo + AbbVie | Pivotal trial | Quizartinib pairs with venetoclax + azacitidine triplet for older adults with AML |
| 2024-2026 | TUSCANY Phase 1/2 (tuspetinib + venetoclax) | Aptose / Hanmi + AbbVie | Clinical milestone | Multikinase + BCL2 combination tests resistance management beyond pure FLT3 |
| 2024-2026 | Crenolanib Phase 3 readouts | Arog Pharmaceuticals | Pivotal trial | Direct competitor to gilteritinib with FLT3-ITD + FLT3-TKD coverage |
Strategic Pattern
Strategic pattern: Overall, the FLT3 inhibitor BD theme is segmentation by mutation and disease setting. Astellas owns R/R monotherapy through gilteritinib; Novartis defends frontline through midostaurin; Daiichi Sankyo claims frontline FLT3-ITD through quizartinib’s QuANTUM-First win; Arog’s crenolanib targets the same Type I dual-mutation niche as gilteritinib. Meanwhile, every sponsor pairs with venetoclax and azacitidine for older adults with AML. The HOVON156/PASHA result protects the existing market segmentation rather than reshaping it.
Unmet Needs & White Spaces
Notably, three white spaces meet all three criteria — sparse coverage, clear technical value, and a realistic entry path:
| White Space | Current Coverage | Technical Value | Entry Path |
|---|---|---|---|
| FLT3-TKD-active frontline regimens (frontline FLT3-mutated AML therapy that covers both ITD and TKD mutations) | Sparse — quizartinib (frontline) misses TKD; midostaurin (frontline) is multikinase but not selective; gilteritinib failed HOVON156/PASHA OS endpoint vs midostaurin | High — TKD-mutated patients have limited frontline options matched to their mutation profile | Crenolanib Phase 3 in frontline + 7+3; gilteritinib subgroup analyses with TKD enrichment; FLT3 PROTAC degrader frontline trials |
| Post-transplant FLT3 maintenance (long-term FLT3 inhibition after allogeneic stem cell transplant) | Sparse — sorafenib used off-label (SORMAIN); MORPHO tests gilteritinib; QuANTUM-First includes maintenance arm | High — relapse after transplant remains the dominant cause of FLT3-mutated AML mortality | MORPHO readout; head-to-head sorafenib vs gilteritinib vs quizartinib in maintenance; oral ergonomic differentiation |
| FLT3 PROTAC degraders for resistance (degraders that overcome F691L and tertiary kinase domain variants) | Sparse — 2023+ patent filings on FLT3 PROTAC scaffolds; no clinical-stage candidate; resistance to gilteritinib via F691L drives unmet need | High — addresses dominant resistance mechanism after second-generation FLT3i exposure | Phase 1 of FLT3 PROTACs in R/R AML who progressed on gilteritinib or quizartinib; combination with venetoclax + azacitidine |
Risks and Strategic Outlook for 2026 and Beyond
Key Risks
- HOVON156/PASHA OS miss: However, the EHA 2026 LB5005 readout shows gilteritinib did not beat midostaurin on OS in newly diagnosed FLT3-mutated AML. Frontline replacement of midostaurin requires EFS or RFS subgroup wins or improved transplant pathways — not just OS.
- Quizartinib frontline competition: Moreover, Vanflyta’s QuANTUM-First OS gain (31.9 vs 15.1 months) sets a high frontline bar. As Daiichi Sankyo runs QuANTUM-Aza and post-transplant maintenance trials, quizartinib expands into settings where gilteritinib competes.
- FLT3 PROTAC degrader displacement: Notably, 2023+ patent filings show academic and biotech interest in FLT3 PROTACs that degrade rather than inhibit FLT3. The architecture could overcome F691L gatekeeper mutations that limit gilteritinib durability.
- Crenolanib Phase 3 readout dependency: Furthermore, Arog’s crenolanib competes head-on with gilteritinib in the Type I dual-mutation niche. A crenolanib win would split the R/R FLT3-mutated AML monotherapy market.
Strategic Outlook
For strategic planning, the safest near-term bet around gilteritinib is R/R monotherapy preservation — keeping ADMIRAL-class evidence as the gold standard for relapsed FLT3-mutated AML while running LACEWING and MORPHO to extend into post-transplant maintenance and older-adult frontline. However, the highest-upside, highest-risk bets are in EFS or RFS subgroup wins from HOVON156/PASHA that justify guideline-level frontline use for specific populations and in FLT3 PROTAC degrader development that addresses F691L resistance. White-space opportunities exist in transplant-pathway differentiation and in frontline TKD-mutation coverage where quizartinib falls short. The next two years of gilteritinib’s competitive position will depend less on absolute survival data and more on which subgroups, regimens, and resistance settings the molecule still owns uniquely.
If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.
Turn Complex Data into Decision-Ready Insights
Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.
- ✔ Domain-specific research Q&A
- ✔ Patent & literature analysis (2 files per upload)
- ✔ Lead compound analysis with SAR extraction (5 runs)
- ✔ 2 AI-powered Pulse briefs for early signals
